Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment

The European Commission has approved the use of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The combination is now licensed for use within the European Union. The Medicines and Healthcare products Regulatory Agency (MHRA) will need to approve the nivolumab plus cabozantinib combination before it […]

read more

Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The European Commission will now review the CHMP recommendation and make a final decision in the next few months […]

read more

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which  stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]

read more

ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer

In a small phase 2 study presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), the novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), showed promising anti-cancer activity in combination with cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) that had been previously treated. Kidney cancers develop […]

read more

ASCO GU 2021: Cabozantinib for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. In this study, the results of which will be presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) […]

read more

ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer

The past couple of years has seen a number of combination therapies for the first-line treatment of advanced/metastatic renal cell carcinoma (RCC) become available. At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco this week, ongoing results from the phase 3 CheckMate-9ER clinical trial with the nivolumab plus cabozantinib […]

read more

Cabozantinib plus nivolumab granted FDA approval for first-line treatment of advanced kidney cancer

The Food and Drug Administration (FDA) in the United States has approved the cabozantinib (Cabometyx) plus nivolumab (Opdivo) combination for first-line treatment of advanced renal cell carcinoma (RCC) based on the results of the Checkmate 9ER trial. Around 20-30% of people are diagnosed with advanced RCC, and 30% of people treated for early stage RCC go on […]

read more

CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival

The US Food and Drug Administration (FDA) has granted the drug CB-839 fast track development status when used in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of drug treatment (including at least one TKI). Fast track status speeds up the review […]

read more

Cabozantinib plus atezolizumab for non-clear cell kidney cancer

In this video interview, Dr Monty Pal from the City of Hope Hospital in California talks about a subset of patients in the COSMIC-021 (cohort 10) with non-clear cell RCC, such as papillary renal cell carcinoma (RCC) and chromophobe RCC. Response rates exceeded 30%, which are very promising findings compared to TKIs alone. However, not […]

read more

Cabozantinib plus atezolizumab combination for advanced kidney cancer

In this study, two doses of cabozantinib were tested in combination with atezolizumab for untreated advanced renal cell carcinoma (RCC). Cabozantinib is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), while atezolizumab is an immune checkpoint inhibitor.  Two doses of cabozantinib were tested; 40 mg and 60 mg. The data were fairly comparable […]

read more
Showing 1 to 10 of 78 results
  TOP